Literature DB >> 19041304

Systemic pathology in aged mouse models of Down's syndrome and Alzheimer's disease.

Seymour Levine1, Arthur Saltzman, Efrat Levy, Stephen D Ginsberg.   

Abstract

Down's syndrome (DS) in humans is caused by trisomy of chromosome 21 (HSA 21). DS patients have a variety of pathologies, including mental retardation and an unusually high incidence of leukemia or lymphoma such as megakaryocytic leukemia. Individuals with DS develop the characteristic neuropathological hallmarks of Alzheimer's disease (AD) in early adulthood, generally by the fourth decade of life. There are several mouse models of DS that have a segmental trisomy of mouse chromosome 16 (MMU 16) with triplicated genes orthologous to HSA 21. These mice display neurodegeneration similar to DS. Although brain pathology in DS models is known, little information is available about other organs. We studied the extraneural pathology in aged DS mice (Ts65Dn, Ts2 and Ts1Cje aged 8 to 24 months) as well as other mouse models of neurodegeneration, including presenilin (PS), amyloid-beta precursor protein (APP), and tau (hTau and JNPL) transgenic mice. An increased incidence of peripheral amyloidosis, positive for amyloid A (AA) but not amyloid-beta peptide (A beta), was found in APP over-expressing and tauopathic mice as compared to non-transgenic (ntg) littermates or to DS mouse models. A higher incidence of lymphoma was found in the DS models, including Ts1Cje that is trisomic for a small segment of MMU 16 not including the App gene, but not in the APP over-expressing mice, suggesting that high APP expression is not the cause of lymphoma in DS. The occurrence of lymphomas in mouse DS models is of interest in relation to the increased incidence of malignant conditions in human DS.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19041304      PMCID: PMC2659493          DOI: 10.1016/j.yexmp.2008.10.006

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  43 in total

1.  Neurotrophins are required for nerve growth during development.

Authors:  K L Tucker; M Meyer; Y A Barde
Journal:  Nat Neurosci       Date:  2001-01       Impact factor: 24.884

2.  Segmental trisomy of murine chromosome 16: a new model system for studying Down syndrome.

Authors:  M T Davisson; C Schmidt; E C Akeson
Journal:  Prog Clin Biol Res       Date:  1990

3.  Prospective study of the prevalence of Alzheimer-type dementia in institutionalized individuals with Down syndrome.

Authors:  F E Visser; A P Aldenkamp; A C van Huffelen; M Kuilman; J Overweg; J van Wijk
Journal:  Am J Ment Retard       Date:  1997-01

4.  Neurodegenerative changes associated with beta-amyloid deposition in the brains of mice carrying mutant amyloid precursor protein and mutant presenilin-1 transgenes.

Authors:  M A Kurt; D C Davies; M Kidd; K Duff; S C Rolph; K H Jennings; D R Howlett
Journal:  Exp Neurol       Date:  2001-09       Impact factor: 5.330

5.  Identification and characterization of a new Down syndrome model, Ts[Rb(12.1716)]2Cje, resulting from a spontaneous Robertsonian fusion between T(171)65Dn and mouse chromosome 12.

Authors:  Angela J Villar; Pavel V Belichenko; Anne Marie Gillespie; Heather M Kozy; William C Mobley; Charles J Epstein
Journal:  Mamm Genome       Date:  2005-02       Impact factor: 2.957

6.  Thymic deficiency in Down's syndrome.

Authors:  S Levin; M Schlesinger; Z Handzel; T Hahn; Y Altman; B Czernobilsky; J Boss
Journal:  Pediatrics       Date:  1979-01       Impact factor: 7.124

7.  Cdk5 is a key factor in tau aggregation and tangle formation in vivo.

Authors:  Wendy Noble; Vicki Olm; Kazuyuki Takata; Evelyn Casey; O Mary; Jordana Meyerson; Kate Gaynor; John LaFrancois; Lili Wang; Takayuki Kondo; Peter Davies; Mark Burns; Ralph Nixon; Dennis Dickson; Yasuji Matsuoka; Michael Ahlijanian; Lit-Fui Lau; Karen Duff
Journal:  Neuron       Date:  2003-05-22       Impact factor: 17.173

8.  Mortality and cancer incidence among individuals with Down syndrome.

Authors:  Deirdre A Hill; Gloria Gridley; Sven Cnattingius; Lene Mellemkjaer; Martha Linet; Hans-Olof Adami; Jorgen H Olsen; Olof Nyren; Joseph F Fraumeni
Journal:  Arch Intern Med       Date:  2003-03-24

9.  Amyloid beta-protein deposition in tissues other than brain in Alzheimer's disease.

Authors:  C L Joachim; H Mori; D J Selkoe
Journal:  Nature       Date:  1989-09-21       Impact factor: 49.962

10.  In vivo MRI identifies cholinergic circuitry deficits in a Down syndrome model.

Authors:  Yuanxin Chen; Victor V Dyakin; Craig A Branch; Babak Ardekani; Dunsheng Yang; David N Guilfoyle; Jesse Peterson; Corrinne Peterhoff; Stephen D Ginsberg; Anne M Cataldo; Ralph A Nixon
Journal:  Neurobiol Aging       Date:  2008-01-03       Impact factor: 4.673

View more
  16 in total

1.  Enhanced generation of intraluminal vesicles in neuronal late endosomes in the brain of a Down syndrome mouse model with endosomal dysfunction.

Authors:  Pasquale D'Acunzo; Tal Hargash; Monika Pawlik; Chris N Goulbourne; Rocío Pérez-González; Efrat Levy
Journal:  Dev Neurobiol       Date:  2019-08-01       Impact factor: 3.964

Review 2.  Exosome release and cargo in Down syndrome.

Authors:  Eric D Hamlett; Angela LaRosa; Elliott J Mufson; Juan Fortea; Aurélie Ledreux; Ann-Charlotte Granholm
Journal:  Dev Neurobiol       Date:  2019-08-06       Impact factor: 3.964

Review 3.  Cognitive Impairment, Neuroimaging, and Alzheimer Neuropathology in Mouse Models of Down Syndrome.

Authors:  Eric D Hamlett; Heather A Boger; Aurélie Ledreux; Christy M Kelley; Elliott J Mufson; Maria F Falangola; David N Guilfoyle; Ralph A Nixon; David Patterson; Nathan Duval; Ann-Charlotte E Granholm
Journal:  Curr Alzheimer Res       Date:  2016       Impact factor: 3.498

4.  Proteomic analysis of six- and twelve-month hippocampus and cerebellum in a murine Down syndrome model.

Authors:  Guido N Vacano; David S Gibson; Abdullah Arif Turjoman; Jeremy W Gawryluk; Jonathan D Geiger; Mark Duncan; David Patterson
Journal:  Neurobiol Aging       Date:  2017-11-26       Impact factor: 4.673

Review 5.  Influence of allelic differences in Down syndrome.

Authors:  Randall J Roper; Laura Hawley; Charles R Goodlett
Journal:  Prog Brain Res       Date:  2019-10-24       Impact factor: 2.453

6.  Glutamatergic transmission aberration: a major cause of behavioral deficits in a murine model of Down's syndrome.

Authors:  Gurjinder Kaur; Ajay Sharma; Wenjin Xu; Scott Gerum; Melissa J Alldred; Shivakumar Subbanna; Balapal S Basavarajappa; Monika Pawlik; Masuo Ohno; Stephen D Ginsberg; Donald A Wilson; David N Guilfoyle; Efrat Levy
Journal:  J Neurosci       Date:  2014-04-09       Impact factor: 6.167

7.  Expression profile analysis of vulnerable CA1 pyramidal neurons in young-Middle-Aged Ts65Dn mice.

Authors:  Melissa J Alldred; Sang Han Lee; Eva Petkova; Stephen D Ginsberg
Journal:  J Comp Neurol       Date:  2014-08-30       Impact factor: 3.215

8.  Uncovering molecular biomarkers that correlate cognitive decline with the changes of hippocampus' gene expression profiles in Alzheimer's disease.

Authors:  Martín Gómez Ravetti; Osvaldo A Rosso; Regina Berretta; Pablo Moscato
Journal:  PLoS One       Date:  2010-04-13       Impact factor: 3.240

9.  Tau downregulates BDNF expression in animal and cellular models of Alzheimer's disease.

Authors:  Elyse Rosa; Sujeivan Mahendram; Yazi D Ke; Lars M Ittner; Stephen D Ginsberg; Margaret Fahnestock
Journal:  Neurobiol Aging       Date:  2016-08-31       Impact factor: 4.673

Review 10.  Molecular genetic analysis of Down syndrome.

Authors:  David Patterson
Journal:  Hum Genet       Date:  2009-06-13       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.